Disappointment for Australian company Actinogen Medical (ASX:ACW) with the release of data from its phase 2 clinical trial (XanADu) investigating its investigative therapy Xanamem in patients with mild dementia due to Alzheimer’s disease.

Latest Video
New Stories
-
Prescient Therapeutics opens share purchase plan
July 2, 2025 - - Australian Biotech -
Amplia Therapeutics announces additional confirmed partial response recorded in ACCENT trial
July 2, 2025 - - Australian Biotech -
Island Pharmaceuticals announces the appointment of new chair
July 2, 2025 - - Australian Biotech -
Wesfarmers Health launches pilot pharmacy format, InstantScripts Pharmacy Health Hub
July 2, 2025 - - Latest News -
New treatment option for early breast cancer at high risk of recurrence
July 2, 2025 - - Latest News -
Expanded listing for Bristol Myers Squibb's PD-1 to include bladder cancer
July 2, 2025 - - Latest News -
The industry backs productivity focus for the Albanese Government's second term
July 2, 2025 - - Latest News